



CHEPLAPHARM ACQUIRES PRODUCT RIGHTS FOR ATACAND® AND ATACAND® PLUS FROM ASTRAZENECA IN EUROPE

CHEPLAPHARM is pleased to announce the acquisition of the commercial rights to ATACAND® (Candesartan Cilexetil) and ATACAND® Plus (fixed-dose combination of Candesartan Cilexetil and Hydrochlorothiazide) in 28 European markets from AstraZeneca.

ATACAND® is a prescription medication for the treatment of heart failure and hypertension. The completion of the transaction is expected for the third quarter of 2018.

“This investment will already contribute significantly to our operating income in the fourth quarter of 2018”, said CHEPLAPHARM’s CEO Sebastian F. Braun. “Furthermore, this agreement matches perfectly with our internationally oriented business strategy and will strengthen our country portfolio and, consequently, realize and further develop our ambitious growth strategy in the respective territories.”

About ATACAND®

ATACAND® (Candesartan Cilexetil), is a selective AT1 subtype angiotensin II receptor. The product is also available in Europe as a fixed-dose combination of Candesartan Cilexetil and Hydrochlorothiazide (ATACAND® Plus). ATACAND® Plus is indicated for the management of hypertension when monotherapy is not sufficiently effective. ATACAND® was developed by AstraZeneca in collaboration with Takeda. Each company holds the exclusive rights to the product in certain markets. In other markets, ATACAND® is co-marketed by both parties.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international Buy And Build Strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe for years with projected annual sales of 350 million euros in 2018.

Please refer to www.cheplapharm.com for additional information.

Press Office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)